For the year ending 2025-12-31, CGON had -$224,578K decrease in cash & cash equivalents over the period. -$132,480K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -160,995 |
| Depreciation and amortization | 1,445 |
| Stock-based compensation expense | 26,676 |
| Accretion of discount on short-term investments | 1,014 |
| Non-cash interest expense (income) | 768 |
| Non-cash lease expense | 34 |
| Prepaid expenses and other current assets | 1,900 |
| Accounts receivable, net | 320 |
| Inventory | 444 |
| Other assets | 1,584 |
| Accounts payable | -1,644 |
| Accrued expenses and other current liabilities | 8,655 |
| Other liabilities | -487 |
| Net cash used in operating activities | -132,346 |
| Proceeds from sales and maturities of investments | 844,139 |
| Purchases of investments | 1,067,860 |
| Acquisition, net of cash acquired | 21,967 |
| Purchases of property and equipment | 134 |
| Net cash used in investing activities | -245,822 |
| Proceeds from follow-on public offerings, net of issuance costs | 147,450 |
| Proceeds from exercise of common stock options | 6,456 |
| Stock issuance costs | 316 |
| Net cash provided by financing activities | 153,590 |
| Net (decrease) increase in cash and cash equivalents | -224,578 |
| Cash and cash equivalents at beginning of period | 257,068 |
| Cash and cash equivalents at end of period | 32,490 |
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)